A Review on: Analytical Techniques Development and Validation of Drugs Used for Alzheimer’s Disease

Pharmaceutical analysis plays a very prominent role in quality assurance as well as quality control of bulk drugs and pharmaceutical formulations. Rapid increase in pharmaceutical industries and production of drug in various parts of the world has brought a rise in demand for new analytical techniques in the pharmaceutical industries. As a consequence, analytical method development has become the basic activity of analysis. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory defeat and impairment in behavior, language and visuospatial skills. Donepezil, rivastigmine, galantamine, tacrine and memantine are the US Food and Drug Administration approved oral drugs used in the treatment of AD. These drugs can provide a symptomatic relief but they poorly affect the progression of the disease. Quantization of these drugs in various biological matrices, dosage forms and monitoring them in long-term treatment is essential to titer the dose of these drugs and ensures patient compliance. The main objective of this review mainly focused on spectrophotometric, high-performance liquid chromatography (HPLC), HPTLC and liquid chromatography-mass spectroscopy (LC-MS) which can be used for method development and validation of different Alzheimer’s drugs. The review is a collection of data including various analytical methods used, the different columns used, mobile phase used, flow rate, different detectors and detection wavelength and retention time. This review includes discussion on method development and validation of Alzheimer’s drugs and newly developed compounds which have lesser side effects and are proving more efficient for treatment of Alzheimer’s disease. This review challenges to researches for development of front line drug for Alzheimer’s disease.